Immunovant Dirección
Dirección controles de criterios 2/4
El CEO de Immunovant es Pete Salzmann , nombrado en Dec 2019, tiene una permanencia de 4.92 años. compensación anual total es $8.55M, compuesta por 8.2% salario y 91.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.3% de las acciones de la empresa, por valor de $11.81M. La antigüedad media del equipo directivo y de la junta directiva es de 3.1 años y 4.9 años, respectivamente.
Información clave
Pete Salzmann
Chief Executive Officer (CEO)
US$8.6m
Compensación total
| Porcentaje del salario del CEO | 8.2% |
| Permanencia del CEO | 4.9yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 3.1yrs |
| Promedio de permanencia en la Junta Directiva | 4.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Oct 16
Immunovant: Switching Lead Candidates Increases Risk
Oct 14We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Jul 18Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive
Jun 27We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Apr 19Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Apr 04Immunovant: An Intriguing And Developing Story
Jan 25Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate
Jan 12We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Sep 28Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Jun 14Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Mar 08We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Nov 06Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset
Oct 17Immunovant stock down on raising $75M though equity capital
Oct 04We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Aug 06Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Apr 06We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Jun 20Immunovant EPS beats by $0.04
Jun 01argenx rise even as Immunovant pauses the trial for anti-FcRn therapy
Feb 03Immunovant slips 7% on voluntary hold of IMVT-1401 dosing
Feb 02Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management
Jan 14Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?
Dec 30Immunovant (IMVT) Investor Presentation - Slideshow
Nov 16Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$323m |
| Jun 30 2024 | n/a | n/a | -US$273m |
| Mar 31 2024 | US$9m | US$700k | -US$259m |
| Dec 31 2023 | n/a | n/a | -US$243m |
| Sep 30 2023 | n/a | n/a | -US$255m |
| Jun 30 2023 | n/a | n/a | -US$245m |
| Mar 31 2023 | US$6m | US$625k | -US$211m |
| Dec 31 2022 | n/a | n/a | -US$199m |
| Sep 30 2022 | n/a | n/a | -US$177m |
| Jun 30 2022 | n/a | n/a | -US$167m |
| Mar 31 2022 | US$6m | US$600k | -US$157m |
| Dec 31 2021 | n/a | n/a | -US$138m |
| Sep 30 2021 | n/a | n/a | -US$128m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | US$15m | US$567k | -US$107m |
| Dec 31 2020 | n/a | n/a | -US$100m |
| Sep 30 2020 | n/a | n/a | -US$79m |
| Jun 30 2020 | n/a | n/a | -US$73m |
| Mar 31 2020 | US$9m | US$361k | -US$66m |
Compensación vs. Mercado: La compensación total de Pete($USD8.55M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.56M).
Compensación vs. Ingresos: La compensación de Pete ha aumentado mientras la empresa no es rentable.
CEO
Pete Salzmann (56 yo)
4.9yrs
Permanencia
US$8,552,430
Compensación
Dr. Peter Salzmann, also known as Pete, M.D., M.B.A. is the Chief Executive Officer and Director of Immunovant, Inc. since December 2019. Dr. Salzmann has served as a member of Immunovant Sciences Ltd.’s b...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairperson of the Board | 4.9yrs | US$3.69m | 0.014% $ 537.6k | |
| CEO & Director | 4.9yrs | US$8.55m | 0.30% $ 11.8m | |
| Chief Technology Officer | 1.6yrs | US$4.04m | sin datos | |
| Chief Financial Officer | 3.1yrs | US$2.07m | 0.091% $ 3.6m | |
| Chief Operating Officer | no data | sin datos | sin datos | |
| Chief Legal Officer & Corporate Secretary | 2.8yrs | sin datos | 0.076% $ 3.0m | |
| Vice President of Marketing | 4.8yrs | sin datos | sin datos | |
| Senior Vice President of Human Resources | no data | sin datos | sin datos | |
| Chief Medical Officer | 3.4yrs | US$1.92m | 0.13% $ 5.3m | |
| Senior Vice President of Strategic Finance | no data | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | 0.016% $ 638.2k | |
| Senior Vice President of Program & Alliance Management | no data | sin datos | sin datos |
3.1yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de IMVT se considera experimentado (3.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairperson of the Board | 4.9yrs | US$3.69m | 0.014% $ 537.6k | |
| CEO & Director | 4.9yrs | US$8.55m | 0.30% $ 11.8m | |
| Independent Director | 4.9yrs | US$291.32k | 0.027% $ 1.0m | |
| Director | 5.1yrs | US$445.00k | 0.012% $ 479.6k | |
| Independent Director | 5.1yrs | US$287.62k | 0.022% $ 869.3k | |
| Independent Director | 4.9yrs | US$436.30k | 0.012% $ 490.3k | |
| Director | 4.8yrs | US$55.00k | sin datos |
4.9yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de IMVT se considera experimentada (4.9 años de antigüedad promedio).